Genomics|Update|Non Communicable Diseases ► Cancer [2]

Genomics|Update|Non Communicable Diseases

Volume 33  Number 23  December 11-18, 2014

Cancer

The 21-gene recurrence score and locoregional recurrence in breast cancer patients 
Jegadeesh NK, et al. Ann Surg Oncol 2014 Dec

Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews 
Marrone M, et al. Genet Med 2014 Dec

Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey
Violette PD, et al. Can Urol Assoc J 2014 Nov;8(11-12):E832-E840

Loss of heterozygosity at the CYP2D6 locus in breast cancer: Implications for germline pharmacogenetic studies
Matthew P. Goetz, et al. JNCI J Natl Cancer Inst (2015) 107 (2): dju401

Mayo Clinic: Genotyping errors plague CYP2D6 testing for tamoxifen therapy, EurekAlert, Dec 9

Prevalence and correlates of receiving and sharing high-penetrance cancer genetic test results: Findings from the Health Information National Trends Survey. 
Taber JM, et al.  Public Health Genomics. 2014 Nov 25

Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic
Walker R, et al. Can Urol Assoc J 2014 Nov;8(11-12):E783-E788

Should a family history of papillary thyroid carcinoma indicate more aggressive therapy in patients with this tumor? 
Rosario PW & Calsolari MR Arq Bras Endocrinol Metabol 2014 Nov;58(8):812-6

Testing for hereditary breast cancer: Panel or targeted testing? Experience from a clinical cancer genetics practice
Doherty J, et al. J Genet Couns 2014 Dec

Updated UK recommendations for HER2 assessment in breast cancer.
Rakha EA, et al. J Clin Pathol. 2014 Dec 8. pii: jclinpath-2014-202571.

Fecal DNA analysis for colorectal cancer screening,  [PDF 223.30 KB] TEC Special Report, BlueCross Blue Shield, Dec 2014